Northern Trust’s Ensysce Biosciences ENSC Stock Holding History

Northern Trust’s Portfolio ENSC Stock Details ENSC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-14	Closed	-$11K	–	4662
2022 Q3	$11K	Buy	+14	New	+$22.8K	﹤0.01%	4633

Other funds holding ENSC

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Northern Trust's ENSC Position: Q4 2022 in Review

Northern Trust sold out of Ensysce Biosciences (ENSC) in Q4 2022, closing a stake of 14 shares — an estimated $11K sold.

Northern Trust first reported a position in ENSC in Q3 2022 and held it in 1 quarter. The position peaked at $11K in Q3 2022. 13 funds tracked by Wall St. Rank hold ENSC as of Q4 2022.

Northern Trust reported no remaining Ensysce Biosciences position as of Q4 2022 after selling out during the quarter.
Northern Trust sold 14 Ensysce Biosciences shares in Q4 2022, an estimated $11K.
Northern Trust first reported a position in Ensysce Biosciences in Q3 2022 and held it in 1 quarter.
Northern Trust's Ensysce Biosciences position peaked at $11K in Q3 2022.
13 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q4 2022.

Based on Northern Trust's 13F filing for Q4 2022, filed 13 Feb 2023.